The National Health Council has advocated for a regulatory pathway for biosimiliars that improves access to existing drug therapies while simultaneously promoting the development of new treatments. Our letter to Congress was posted on the Web in June. **

The AP described only part of our position – the part that calls for 10 years of data exclusivity similar to other international standards. The reporter did not address our call to use data exclusivity to encourage the development of treatments for conditions with limited or no treatments, such as ALS or lupus. In doing so he implied our position had been inappropriately influenced by drug manufacturers. Our policy on corporate relations publicly defines our relationship with business and industry. **

NHC has been clear in its cause to foster research & development that leads to breakthrough treatments so desperately needed by patients.

Emily Noonan
Manager, Communications and Marketing
National Health Council